NCT00087035 - Docetaxel and Erlotinib in Treating Older Patients With Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

June 30, 2006

Study Completion Date

March 31, 2008

Conditions

Prostate Cancer

Interventions

DRUG

docetaxel

Administered as an IV infusion of 60m/m2 over a 1-hour period, once every 21 ± 2 days

DRUG

erlotinib hydrochloride

Will be taken at a starting daily dose of 150mg

Trial Locations (3)

Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles

Jonsson Comprehensive Cancer Center at UCLA, Los Angeles

University Cancer Center at University of Washington Medical Center, Seattle